Clinical Data Managers

15-2051.02

Median wage $120,230/yr262,440 employed (US)Rank #133 of 923 scored · top 14% by substitution

Apply knowledge of health care and database management to analyze clinical data, and to identify and report trends.

Sub-scores

0–100 · band = confidence interval from rater disagreement

Substitution43

Exposure44

Augmentation73

Substitution — the headline: capability discounted by cost, barriers and adoption.

Exposure — technical capability alone, regardless of whether anyone deploys it.

Augmentation — how much AI assists without replacing. High here + moderate substitution = a changing job, not a disappearing one.

Tasks on the substitution scale

21 rated tasks, binned by substitution score.

Position among all scored occupations

Distribution of 923 occupation scores; the marker is this occupation.

Tasks with substitution ≥ 70

Run 1.0.0-draft.1 · computed 2026-08-05 · rater panel: claude-sonnet-5, claude-haiku-4-5-20251001 · intervals span rater disagreement.

Why this score

The five weighted dimensions of the composite, averaged across this occupation's tasks (importance-weighted, panel mean). Exact weights and formulas: /api/v1/methodology.

Task automatabilityw 35%46

panel mean rating 2.8/5 → substitution pressure 46/100

Technical feasibility todayw 20%40

panel mean rating 2.6/5 → substitution pressure 40/100

Cost vs. human wagew 15%44

panel mean rating 2.7/5 → substitution pressure 44/100

Adoption barriersw 20%inverted — strong barriers lower the score42

panel mean rating 3.3/5 (barrier strength) → substitution pressure 42/100

Sector adoption velocityw 10%38

panel mean rating 2.5/5 → substitution pressure 38/100

Task breakdown (21 tasks)

Substitution pressure per task, weighted by O*NET importance in the composite. Expand a task for the full rater audit trail — every rating, every model, every rationale.

Track the flow of work forms, including in-house data flow or electronic forms transfer.

CI 75–92 · exposure 87 · augmentation 75 · importance 3.5/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Healthcare IT and clinical trial organizations are actively adopting RPA and electronic data capture/workflow platforms to manage form flow and reduce manual data handling. The sector is digitizing rapidly, with many organizations in active production deployment of such systems.
Sector adoption velocity	claude-sonnet-5	4/5	Clinical research and pharma have already widely adopted electronic data capture and workflow tracking systems, representing mature digitization in a semi-regulated but tech-forward sector.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI-assisted form tracking and workflow visibility tools help data managers prioritize bottlenecks, predict delays, and optimize routing by highlighting at-risk forms and suggesting next actions. This augmentation significantly enhances human oversight and decision-making around work prioritization while reducing manual status checks.
Augmentation potential	claude-sonnet-5	4/5	AI-enhanced dashboards and automated alerts significantly improve a data manager's ability to monitor and prioritize form flow issues, though human oversight remains for compliance and data quality judgment.
Task automatability	claude-haiku-4-5-20251001	5/5	Tracking work forms and managing data flow—whether paper or electronic—is highly repetitive and rule-based, involving document receipt, logging, status updates, and routing. Current RPA systems, workflow automation tools, and document management platforms can handle this end-to-end with significant time savings by automating form capture, data extraction, status tracking, and escalation alerts.
Task automatability	claude-sonnet-5	4/5	Tracking document/form flow through a defined pipeline is largely a status-tracking and workflow-orchestration task that clinical data management (CDMS/EDC) systems and workflow automation tools already handle well, with humans mainly reviewing exceptions.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Few legal or regulatory barriers prevent automating form tracking itself; most HIPAA and data governance concerns apply equally to human handlers. However, organizations may require oversight integration and audit trails, and legacy system integration can create modest friction, but these are surmountable implementation challenges rather than hard restrictions.
Adoption barriers	claude-sonnet-5	2/5	No licensure is required to track workflow, but regulatory frameworks (GCP, 21 CFR Part 11) require audit trails and validated systems, creating moderate compliance friction.
Cost vs. human wage	claude-haiku-4-5-20251001	5/5	RPA and workflow automation solutions are typically deployed at a fraction of the cost of a full-time clinical data manager once configured. The per-transaction cost of automated form tracking and routing is orders of magnitude lower than human labor, with minimal ongoing operational overhead.
Cost vs. human wage	claude-sonnet-5	4/5	Automated workflow tracking software costs a fraction of a dedicated data manager's time spent manually monitoring form status, though some licensing and integration costs remain.
Technical feasibility today	claude-haiku-4-5-20251001	5/5	Mature products in robotic process automation (UiPath, Blue Prism, Automation Anywhere) and enterprise workflow platforms (ServiceNow, Workiva) already perform form tracking and data flow management at scale in healthcare and clinical settings. These systems are deployed in production across many organizations with reliable performance.
Technical feasibility today	claude-sonnet-5	4/5	Clinical trial management systems, EDC platforms (e.g., Medidata, Veeva) and workflow automation tools reliably track form status, queries, and transfers in production today across many trial sites.

Prepare appropriate formatting to data sets as requested.

CI 62–72 · exposure 70 · augmentation 88 · importance 4.0/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	3/5	Healthcare IT is moderately digitized and cautious; while data automation tools are increasingly adopted in large hospital systems and CROs, clinical data teams often move slowly due to validation requirements and risk-averse governance, typical of mid-stage adoption.
Sector adoption velocity	claude-sonnet-5	3/5	Pharma and clinical research sectors are increasingly adopting automation and AI for data management, but adoption is tempered by regulatory validation requirements, placing it in the middle of the adoption curve.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI can significantly assist data managers by auto-generating formatting rules, flagging anomalies, and pre-populating standardized conversions, enabling humans to focus on validation and exception handling rather than repetitive transformation work.
Augmentation potential	claude-sonnet-5	5/5	AI and scripting tools substantially speed up dataset formatting tasks, letting clinical data managers focus on validation and quality checks rather than manual restructuring.
Task automatability	claude-haiku-4-5-20251001	4/5	Data formatting tasks are highly structured and rule-based, involving column renaming, standardization, and cleaning—all well-suited to AI automation. Current systems can handle ~70% of typical formatting requests reliably; remaining 30% often requires context-specific domain knowledge or exception handling that still needs human review.
Task automatability	claude-sonnet-5	4/5	Reformatting clinical datasets (renaming variables, restructuring layouts, applying standard formats like SDTM) is a rule-based transformation task well-suited to scripting and AI-assisted coding tools, achieving significant time savings over manual work.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Data formatting in clinical settings is subject to regulatory scrutiny (HIPAA, FDA 21 CFR Part 11) and data governance policies, creating organizational and compliance friction, but no hard legal requirement that only a licensed human must perform it—QA and spot-checks still occur.
Adoption barriers	claude-sonnet-5	3/5	Clinical trial data is subject to regulatory requirements (e.g., FDA, GCP) requiring audit trails and qualified personnel sign-off, creating moderate compliance friction even though the technical task itself is automatable.
Cost vs. human wage	claude-haiku-4-5-20251001	4/5	A single AI/automation system can handle formatting for many datasets at near-zero marginal cost per task once configured, compared to a clinical data manager's hourly wage; the cost advantage is substantial on repetitive formatting work.
Cost vs. human wage	claude-sonnet-5	4/5	Automated scripting and AI-assisted formatting is dramatically cheaper per dataset than manual reformatting by skilled clinical data managers, though some oversight cost remains.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Deployed products like Trifacta, Alteryx, and Python-based automation frameworks handle data formatting reliably in production at scale, though some organizations still rely on custom scripting and manual QA steps to catch edge cases.
Technical feasibility today	claude-sonnet-5	3/5	Tools like clinical data management platforms and AI coding assistants (e.g., for SAS/R scripts) can perform much of this reliably, but validated production systems still require human review to meet regulatory data integrity standards.

Write work instruction manuals, data capture guidelines, or standard operating procedures.

CI 50–76 · exposure 70 · augmentation 88 · importance 3.6/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	3/5	Healthcare and clinical research organizations are piloting AI-assisted documentation tools, but adoption remains mixed; large institutions with digital infrastructure move faster, while smaller sites lag, and regulatory conservatism slows deep production deployment compared to information-sector adoption rates.
Sector adoption velocity	claude-sonnet-5	3/5	Clinical research and pharma are moderately digitized with growing pilot use of generative AI for documentation, but conservative, regulated environments slow full production deployment.
Augmentation potential	claude-haiku-4-5-20251001	5/5	AI can dramatically accelerate guideline drafting, version management, and multi-format output (web, PDF, training modules) while clinical data managers retain review, compliance validation, and field adaptation—creating high productivity lift while preserving human judgment on clinical and regulatory nuance.
Augmentation potential	claude-sonnet-5	4/5	AI is well-suited to accelerate drafting, formatting, and standardizing language for manuals and SOPs, meaningfully boosting productivity while humans retain responsibility for accuracy and compliance.
Task automatability	claude-haiku-4-5-20251001	5/5	AI can generate complete work instruction manuals, data capture guidelines, and SOPs end-to-end by extracting requirements from clinical protocols, databases, and existing documentation, delivering output that meets the 50% time-saving threshold with minimal human revision for technical accuracy and compliance alignment.
Task automatability	claude-sonnet-5	3/5	AI can draft substantial portions of SOPs and data capture guidelines from templates or examples, but accuracy for clinical/regulatory compliance requires significant human review and domain-specific customization, limiting full end-to-end automation.
Adoption barriers	claude-haiku-4-5-20251001	3/5	Regulatory oversight (FDA, ICH-GCP, HIPAA) and organizational quality control processes create material friction; while no legal mandate requires a human author, healthcare organizations typically require documented human sign-off and accountability for SOPs and data governance procedures, adding oversight layers.
Adoption barriers	claude-sonnet-5	3/5	No licensing requirement mandates a human author, but regulatory frameworks (GxP, FDA guidance) demand accountable, qualified personnel to approve and own SOPs, creating meaningful oversight friction.
Cost vs. human wage	claude-haiku-4-5-20251001	4/5	AI inference and integration costs for generating these documents are substantially lower than the loaded wage of a clinical data manager, with the cost ratio favoring automation by a significant margin when factoring in document volume and iteration cycles.
Cost vs. human wage	claude-sonnet-5	3/5	Drafting time can be reduced substantially, but the need for expert review, compliance checks, and validation against regulatory standards keeps overall cost savings moderate rather than order-of-magnitude.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Large language models and specialized documentation tools are actively deployed in healthcare and clinical settings to draft procedures and guidelines; outputs are reliable for structure and content generation, though human expert review for clinical specificity and regulatory compliance remains standard practice.
Technical feasibility today	claude-sonnet-5	3/5	Generative AI tools are used in pharma/clinical operations to draft documentation, but production use for regulated SOPs still requires heavy human editing and validation, so reliability is moderate rather than proven at scale.

Develop or select specific software programs for various research scenarios.

CI 25–87 · exposure 58 · augmentation 88 · importance 3.1/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Healthcare informatics and clinical research sectors are rapidly adopting AI-assisted development and software evaluation tools; major research institutions and CROs are actively deploying code-generation and requirements-analysis AI in production workflows.
Sector adoption velocity	claude-sonnet-5	2/5	Clinical data management is a regulated, specialized niche within life sciences with cautious, slow-moving technology adoption due to compliance and validation burdens.
Augmentation potential	claude-haiku-4-5-20251001	5/5	AI dramatically augments this task by instantly generating comparison matrices, automating vendor API testing, drafting custom scripts, and surfacing integration considerations, enabling a single data manager to evaluate and configure systems far faster than manual methods.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants and knowledge tools can meaningfully speed up drafting specifications, comparing software options, and generating code snippets, augmenting the data manager's decision-making process.
Task automatability	claude-haiku-4-5-20251001	5/5	AI can currently perform software selection and evaluation at scale by analyzing requirements, comparing vendor documentation, testing APIs, and recommending appropriate tools. Modern AI systems can also generate custom scripts or small programs for standard research scenarios, meeting the 50% time-saving threshold for much of this task.
Task automatability	claude-sonnet-5	2/5	Selecting or developing software requires understanding regulatory context, study design, data standards (CDISC, etc.) and institutional constraints that go beyond current AI's autonomous capability; AI can assist but not fully replace this judgment-heavy task.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Clinical research typically operates under regulatory frameworks (FDA, IRB) that scrutinize tools and validation, creating modest compliance friction, but no hard legal requirement mandates a licensed human perform software selection itself—validation is the barrier, not authorization.
Adoption barriers	claude-sonnet-5	4/5	Clinical research software must comply with FDA 21 CFR Part 11, GCP, and validation requirements, requiring qualified professionals to select/validate systems, creating substantial regulatory and liability barriers.
Cost vs. human wage	claude-haiku-4-5-20251001	5/5	AI inference costs for software selection and custom script generation are negligible compared to loaded salaries of clinical data managers ($70k–$100k+), yielding an order-of-magnitude cost advantage for routine selection and development tasks.
Cost vs. human wage	claude-sonnet-5	2/5	While AI coding tools reduce some development time, the oversight, validation, and regulatory compliance review needed for clinical research software keeps overall costs comparable to or only modestly below human-led processes.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Deployed products like Claude, GPT-4, and specialized code-generation tools (GitHub Copilot, Replit) reliably assist with software selection, evaluation, and basic custom program development. Production use is widespread in research organizations, though final validation and integration still typically require human oversight.
Technical feasibility today	claude-sonnet-5	2/5	No deployed product autonomously selects or builds clinical data management software for research studies end-to-end; existing AI coding assistants help write scripts but don't independently make validated software selection decisions.

Process clinical data, including receipt, entry, verification, or filing of information.

CI 43–67 · exposure 62 · augmentation 88 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Healthcare and clinical research remain digitally conservative sectors with fragmented IT systems, risk-averse governance, and strict compliance requirements; while RPA and document automation pilots exist, production adoption of autonomous clinical data processing remains limited and slow.
Sector adoption velocity	claude-sonnet-5	3/5	Pharma/clinical research has adopted EDC and automated validation tools widely, but full end-to-end automation of data management remains partial due to regulatory caution and legacy systems.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI assists substantially here: intelligent forms auto-population, real-time validation flagging anomalies, and automated cross-checking of data consistency meaningfully reduce human effort and error without removing the clinical data manager from verification and sign-off responsibilities.
Augmentation potential	claude-sonnet-5	5/5	AI-assisted validation, anomaly detection, and auto-population from source documents significantly boost clinical data manager productivity while humans retain oversight for compliance and quality.
Task automatability	claude-haiku-4-5-20251001	3/5	Routine data entry and verification can be partially automated via OCR, form parsing, and rule-based validation, but clinical data requires careful handling of ambiguities, cross-reference checks, and domain-specific interpretation that still demands human oversight. Current AI can automate perhaps 40-50% of receipt and filing workflows but struggles with exception handling and complex contextual verification.
Task automatability	claude-sonnet-5	4/5	Data entry, verification against source documents, and filing are highly structured, rule-based tasks that current AI/automation (OCR, EDC systems with validation logic, RPA) can handle with substantial time savings, though edge cases and query resolution still need human review.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical data handling is heavily regulated under HIPAA, FDA regulations, and Good Clinical Practice (GCP) standards, which typically require audit trails and human accountability; many institutions legally or contractually mandate human verification of data entry and cannot fully delegate to automation without regulatory review.
Adoption barriers	claude-sonnet-5	3/5	Regulatory requirements (GCP, FDA 21 CFR Part 11) mandate audit trails, validation, and accountability for clinical data integrity, creating moderate compliance friction even though the task itself isn't legally restricted to a licensed human.
Cost vs. human wage	claude-haiku-4-5-20251001	3/5	AI-powered data entry and verification tools cost roughly comparable to hiring junior staff per unit output when including licensing, setup, integration, and required human oversight, making the economics marginal rather than strongly favorable.
Cost vs. human wage	claude-sonnet-5	4/5	Automated data entry and validation checks cost far less per record than manual data management labor, though clinical-grade systems require compliance overhead (21 CFR Part 11, audit trails) that adds some cost.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Products exist for clinical data processing (e.g., intelligent document capture, RPA for workflows), but they require significant configuration per institution and typically have error rates requiring human review of 10-20% of records, making them tools rather than fully independent performers.
Technical feasibility today	claude-sonnet-5	4/5	Electronic Data Capture (EDC) systems like Medidata Rave and Veeva already automate much of receipt, entry, and validation with edit checks in production clinical trials, though full autonomous processing without human review is still limited.

Generate data queries, based on validation checks or errors and omissions identified during data entry, to resolve identified problems.

CI 48–55 · exposure 50 · augmentation 75 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Healthcare IT adoption of automation lags information/finance sectors, and clinical data management remains conservative due to compliance sensitivity and reliance on established vendor tools rather than cutting-edge AI integration.
Sector adoption velocity	claude-sonnet-5	3/5	Clinical data management sits within pharma/biotech, a sector with moderate digitization and increasing EDC automation, but AI-driven (vs. rule-based) query generation is still in pilot/early production stages rather than deeply embedded.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI excels at drafting query syntax, suggesting WHERE clauses from error logs, and speeding up boilerplate work; a data manager using AI-assisted query generation can work substantially faster while maintaining quality control and judgment on what to validate.
Augmentation potential	claude-sonnet-5	4/5	AI-assisted query generation meaningfully speeds up identification and drafting of queries from validation errors, letting clinical data managers focus on judgment-heavy resolution and review rather than manual query drafting.
Task automatability	claude-haiku-4-5-20251001	3/5	AI can generate SQL/data queries from error descriptions and assist in formulating query logic, but validation check interpretation and context-specific problem diagnosis often require domain expertise and manual refinement. Current systems handle template-based query generation well but struggle with novel error patterns.
Task automatability	claude-sonnet-5	3/5	AI can generate data queries from validation rule violations and flag discrepancies, but resolving ambiguous or judgment-heavy queries in clinical data (e.g., protocol-specific nuances) still requires human review, so only part of this workflow meets the 50% time-saving bar off-the-shelf.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Healthcare data handling is regulated (HIPAA, GDPR) but the query generation task itself is not legally restricted to humans; oversight is required but not a hard legal barrier. Healthcare organizations show some caution around automation in clinical workflows.
Adoption barriers	claude-sonnet-5	3/5	Clinical trial data management is subject to GCP and regulatory requirements (e.g., FDA 21 CFR Part 11) requiring documented review and audit trails, creating oversight friction, though the query-generation step itself is not inherently reserved for a licensed professional.
Cost vs. human wage	claude-haiku-4-5-20251001	3/5	API costs for AI query generation are low per query, but integration, validation overhead, and human review time roughly offset the savings compared to a skilled data manager's hourly cost for query writing.
Cost vs. human wage	claude-sonnet-5	3/5	Automated query generation via existing EDC rule engines is cheap to run, but the setup, validation, and oversight required to ensure regulatory-grade accuracy make the all-in cost only moderately cheaper than a trained clinical data manager's time.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Products like code-generation AI (GitHub Copilot, Claude) can generate working queries from prompts, and some clinical data platforms include query builders with AI assistance. However, these require careful human validation and don't reliably produce production-ready queries without oversight.
Technical feasibility today	claude-sonnet-5	3/5	EDC/CDMS platforms (e.g., Medidata Rave, Veeva) already include automated edit-check-triggered query generation, but these are largely rule-based rather than fully AI-driven, and true LLM-based query drafting for complex clinical scenarios is still emerging in production.

Provide support and information to functional areas such as marketing, clinical monitoring, and medical affairs.

CI 32–67 · exposure 45 · augmentation 75 · importance 2.8/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	3/5	Pharma and biotech are moderately digitized sectors adopting clinical data analytics tools, but full end-to-end automation of support delivery remains in pilot phase at many organizations; adoption is faster in larger firms with IT investment, slower in smaller CROs.
Sector adoption velocity	claude-sonnet-5	3/5	Pharma and clinical operations are adopting AI tools for data queries and reporting at a moderate pace, with pilots more common than full production deployment for this specific support function.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI significantly assists clinical data managers by auto-generating summaries, answering routine queries from internal stakeholders, and surfacing relevant data quickly, which raises their productivity and allows them to focus on complex interpretation and relationship-building with functional areas.
Augmentation potential	claude-sonnet-5	4/5	AI can significantly assist by quickly retrieving, summarizing, and formatting clinical data information for marketing, monitoring, and medical affairs teams, boosting efficiency while the human remains the primary liaison.
Task automatability	claude-haiku-4-5-20251001	4/5	Current AI systems can automate large portions of information gathering, report generation, and routing to functional areas using LLMs and document processing tools, achieving significant time savings. However, some domain-specific clinical judgment and context-awareness still requires human review, preventing a perfect 5.
Task automatability	claude-sonnet-5	2/5	This task involves cross-functional communication, ad hoc requests, and contextual judgment about what information is relevant to different stakeholders, which current AI cannot fully replicate end-to-end.','rating_note':1},
Adoption barriers	claude-haiku-4-5-20251001	2/5	While clinical data is regulated (HIPAA, 21 CFR Part 11), the support and information-provision task itself has few hard legal barriers to automation; oversight and audit trails are needed but manageable, and organizations rarely require a licensed human to sign off on routine support delivery.
Adoption barriers	claude-sonnet-5	3/5	No strict licensing requirement blocks AI use, but clinical data governance, compliance sensitivities, and internal trust in interdepartmental communications create moderate friction.
Cost vs. human wage	claude-haiku-4-5-20251001	4/5	AI-driven information systems and automated report generation are substantially cheaper than dedicated clinical data manager time for routine queries and support, with integration costs amortized across multiple users. All-in costs are typically well below human labor costs.
Cost vs. human wage	claude-sonnet-5	2/5	Human clinical data managers add judgment and relationship context that AI cannot yet replace, so full automation cost savings are limited even though some query support could be cheaper.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Deployed products (business intelligence platforms, document automation, chatbots for internal support) can handle parts of this task in production, but performance is uneven—error rates remain material for sensitive clinical data, and scope is often narrow to specific functional areas.
Technical feasibility today	claude-sonnet-5	2/5	AI chatbots and data query tools exist to surface information, but no deployed product reliably handles the full scope of cross-departmental support and consultative interaction described here.

Supervise the work of data management project staff.

CI 7–87 · exposure 45 · augmentation 63 · importance 3.4/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Clinical research and healthcare IT sectors are digitizing rapidly, with widespread adoption of electronic data capture and project management platforms; AI-driven supervision tools are already being deployed in fast-moving pharmaceutical and biotech firms.
Sector adoption velocity	claude-sonnet-5	2/5	While clinical data management as a field uses digital tools, actual supervisory/managerial functions are not being replaced by AI agents; adoption is limited to supporting analytics, not the supervisory act itself.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI systems can significantly enhance a human supervisor's productivity by automatically generating status reports, predicting delays, recommending task reassignments, and surfacing anomalies, allowing the supervisor to focus on mentoring and strategic decisions.
Augmentation potential	claude-sonnet-5	3/5	AI can assist supervisors via dashboards, automated quality checks, workload tracking, and performance analytics, improving efficiency of oversight tasks even though the supervisory role itself stays human-led.
Task automatability	claude-haiku-4-5-20251001	5/5	Supervising data management project staff involves tracking task completion, identifying bottlenecks, assigning work, and monitoring productivity—all readily automatable through project management systems and AI agents that log progress, flag delays, and route tasks. Current tools can perform these functions end-to-end with significant time savings.
Task automatability	claude-sonnet-5	1/5	Supervising staff requires interpersonal leadership, performance evaluation, and human judgment that current AI cannot perform end-to-end.atable This is a managerial/people function, not a data-processing task.
Adoption barriers	claude-haiku-4-5-20251001	2/5	While some organizations prefer human managers for team morale and sensitive personnel decisions, there are no legal requirements that a licensed human must supervise data staff; automation faces only moderate organizational friction and cultural preference.
Adoption barriers	claude-sonnet-5	4/5	Supervisory responsibility typically carries organizational accountability, HR/legal responsibility for personnel decisions, and requires a human manager of record, creating strong structural barriers to automation.
Cost vs. human wage	claude-haiku-4-5-20251001	5/5	Automating supervision via project management AI costs a small fraction of a manager's fully loaded salary (typically $80k–$120k annually), making the cost ratio at least an order of magnitude in favor of AI.
Cost vs. human wage	claude-sonnet-5	1/5	There is no AI substitute performing this supervisory role, so no meaningful cost comparison favors AI; a human manager remains necessary regardless of tool cost.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Mature project management and workflow automation platforms (Jira, Monday.com, Asana with AI plugins, plus AI-driven resource allocation systems) reliably handle staff supervision tasks in production at scale, though some nuanced personnel decisions may still require human judgment.
Technical feasibility today	claude-sonnet-5	1/5	No deployed AI product supervises human employees autonomously; management software provides tracking dashboards but not supervisory judgment or accountability.

Analyze clinical data using appropriate statistical tools.

CI 40–50 · exposure 45 · augmentation 75 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	3/5	Adoption of AI-assisted statistical tools in clinical research and healthcare is growing but remains inconsistent; while pilots are common, most organizations still rely on traditional software and human analysts, with deeper integration occurring mainly in large pharma and research institutions.
Sector adoption velocity	claude-sonnet-5	3/5	Pharma and clinical research sectors are adopting AI/ML tools for data analysis at a moderate pace, with pilots and validated tools emerging but full production deployment still limited due to regulatory scrutiny.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI systems substantially augment clinical data managers by automating routine computations, suggesting appropriate tests, generating preliminary reports, and flagging anomalies, enabling analysts to focus on interpretation and clinical relevance while maintaining human oversight of analytical decisions.
Augmentation potential	claude-sonnet-5	4/5	AI substantially augments clinical data managers by automating routine calculations, flagging anomalies, and suggesting appropriate statistical models, while humans retain responsibility for interpretation and regulatory compliance.
Task automatability	claude-haiku-4-5-20251001	3/5	Current AI systems can perform standard statistical analyses (descriptive statistics, basic hypothesis tests, regression) on well-structured clinical data with significant time savings, but complex analytical workflows involving data validation, assumption checking, and interpretation of nuanced clinical context typically require human judgment and setup, limiting full automation to roughly 50% of the work.
Task automatability	claude-sonnet-5	3/5	AI can perform many standard statistical analyses (descriptive stats, regression, survival analysis) with proper setup, but selecting appropriate methods, validating assumptions, and interpreting results in a regulated clinical trial context still requires substantial human oversight.4Automation would need careful validation before achieving 50% time savings at equal quality across the full task.
Adoption barriers	claude-haiku-4-5-20251001	3/5	Clinical data analysis operates under regulatory frameworks (FDA, GCP) and organizational oversight requirements that typically demand a qualified human to validate methodology and results; institutional friction around data governance and audit trails also creates friction, though the task itself is not legally restricted to a licensed professional.
Adoption barriers	claude-sonnet-5	4/5	Clinical data analysis in regulated trials typically requires sign-off by qualified biostatisticians or clinical data managers under GCP/FDA guidelines, creating strong liability and regulatory barriers to full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	3/5	The cost of running statistical analyses via AI inference, data integration, and required human oversight is roughly comparable to the hourly rate of a clinical data manager performing standard analyses; automation saves mostly in execution speed rather than labor elimination.
Cost vs. human wage	claude-sonnet-5	3/5	AI/statistical software can reduce computation time significantly, but the need for expert oversight, validation, and regulatory documentation keeps overall costs roughly comparable to skilled human analysts in this domain.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Statistical software and AI-assisted analysis tools exist in production environments (SAS, R, Python-based systems with auto-statistical packages), but they require careful data preparation, human specification of appropriate tests, and validation of results—error rates remain material when clinical context and regulatory compliance matter.
Technical feasibility today	claude-sonnet-5	2/5	While statistical software and some AI-assisted analytics tools exist, deployed products that reliably perform clinical trial-grade statistical analysis end-to-end without expert statistician review are not yet standard in production regulated environments.

Read technical literature and participate in continuing education or professional associations to maintain awareness of current database technology and best practices.

CI 28–59 · exposure 42 · augmentation 75 · importance 3.3/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	1/5	Adoption of AI to replace this task is minimal; while some organizations use AI summaries as assistive tools, this is a foundational professional responsibility that remains almost entirely human-performed in clinical and healthcare settings with limited sector-wide automation.
Sector adoption velocity	claude-sonnet-5	3/5	Clinical data management sits in a moderately digitized, regulated sector (life sciences/healthcare IT) with growing but not yet universal AI tool adoption for research and literature monitoring.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI tools for literature summarization, filtering by relevance, and alerting to emerging technologies can substantially augment a clinical data manager's productivity in staying current, allowing them to scan more sources and synthesize broader awareness while retaining human judgment over interpretation.
Augmentation potential	claude-sonnet-5	4/5	AI significantly aids in filtering, summarizing, and surfacing relevant literature and trends, saving time for the human who still must interpret and apply insights and engage in professional networking.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can summarize technical literature and flag relevant content, the task fundamentally requires human judgment to evaluate emerging technologies, assess applicability to organizational needs, and maintain professional relationships through association participation—activities requiring contextual decision-making that AI cannot fully automate end-to-end.
Task automatability	claude-sonnet-5	3/5	AI can summarize and synthesize technical literature quickly, but 'maintaining awareness' also involves ongoing judgment, networking, and professional engagement that isn't fully automatable end-to-end.'
Adoption barriers	claude-haiku-4-5-20251001	4/5	Professional development and staying current in one's field is often a stated competency expectation and career requirement; organizational culture, professional identity, and implicit expectations that practitioners maintain their own expertise create strong friction against full automation or substitution.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement blocks AI assistance here, though professional development often carries organizational or certification expectations that favor human engagement in associations and CE credits.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	The task is primarily human time spent reading and attending events; AI assistance (summarization, filtering) can reduce reading time modestly, but the core time investment remains human-driven, and the cost-benefit ratio favors human involvement at current AI capability levels.
Cost vs. human wage	claude-sonnet-5	4/5	AI-based literature summarization and alerting tools are far cheaper than dedicating significant human hours to reading and synthesizing technical literature.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	AI tools can reliably extract information from technical literature and generate summaries, but deployed products lack the nuance to replace human evaluation of best practices or genuine professional association participation, which involves networking and judgment calls beyond text processing.
Technical feasibility today	claude-sonnet-5	3/5	Products like AI summarization tools, research assistants, and literature review aids exist and are used in production, but they don't reliably replace continuous professional awareness-building without human curation.

Prepare data analysis listings and activity, performance, or progress reports.

CI 34–43 · exposure 45 · augmentation 75 · importance 4.0/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Clinical and life-sciences organizations operate in highly regulated, slower-moving environments with strong compliance cultures. Adoption of automation in data management is cautious and incremental, largely limited to lower-risk support tasks rather than full report ownership.
Sector adoption velocity	claude-sonnet-5	2/5	Pharma and clinical research sectors are historically slow adopters of AI in core regulated workflows due to validation and compliance overhead, though data automation tools are gradually being piloted.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI assistants excel at augmenting clinical data managers by automating data pulls, generating first-draft reports, flagging anomalies, and handling formatting—substantially raising productivity while the human retains critical oversight and clinical judgment responsibilities.
Augmentation potential	claude-sonnet-5	4/5	AI can meaningfully speed up drafting of listings, summarizing trends, and generating first-pass report narratives, giving clinical data managers a substantial productivity boost while they retain oversight and final validation.
Task automatability	claude-haiku-4-5-20251001	3/5	Approximately half of the report generation process can be automated—extracting data, aggregating metrics, and producing templated sections with standard formatting. However, validation, interpretation of clinical significance, and narrative synthesis require human judgment and clinical context that current AI struggles to perform reliably.
Task automatability	claude-sonnet-5	3/5	AI can generate data listings and draft summary reports from structured clinical trial data, but ensuring regulatory accuracy, correct statistical interpretation, and audit-ready formatting still requires substantial human setup and validation., so only partial time savings are realized without significant configuration.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical data management operates under strict FDA, regulatory, and audit requirements; data governance mandates human accountability for report accuracy and compliance. Regulatory bodies typically require a qualified human (often a certified data manager) to verify and sign off on analysis listings, creating a legal barrier to full automation.
Adoption barriers	claude-sonnet-5	4/5	Clinical trial data reporting is subject to GxP, FDA, and other regulatory requirements demanding qualified personnel sign-off and audit trails, creating strong compliance-driven barriers to full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	While AI can reduce labor hours on routine data extraction and formatting, clinical data managers command moderate salaries and the oversight, validation, and integration costs for AI systems offset savings. Full automation is rare, keeping costs competitive rather than dramatically cheaper.
Cost vs. human wage	claude-sonnet-5	3/5	AI tools can reduce time spent on drafting listings and reports, but validation, QC, and regulatory review by trained personnel remain necessary, keeping overall costs only moderately lower than fully manual processes.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Products exist for automated report generation and data aggregation (e.g., BI tools, statistical software with automation), but they require material setup, validation, and human oversight. Error rates remain material in clinical contexts where accuracy is critical, limiting full substitution.
Technical feasibility today	claude-sonnet-5	2/5	Some clinical data platforms include automated reporting features, but fully reliable, production-grade generation of compliant analysis listings and progress reports in regulated clinical trial environments is not yet widespread or mature.

Perform quality control audits to ensure accuracy, completeness, or proper usage of clinical systems and data.

CI 25–45 · exposure 38 · augmentation 75 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Clinical data management is highly regulated and risk-averse; adoption of autonomous QC automation lags far behind less-regulated sectors. Most organizations remain in pilot or early adoption phases, with human-led audits still the standard practice.
Sector adoption velocity	claude-sonnet-5	3/5	Pharma and clinical research sectors have adopted electronic data capture and automated edit checks fairly widely, but AI-driven autonomous auditing agents remain in pilot or narrow-scope deployment rather than full production replacement.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI tools can meaningfully assist auditors by automating routine checks, flagging statistical outliers, and highlighting suspicious patterns, substantially raising their throughput and consistency. The human auditor remains responsible for judgment and sign-off, making this a strong augmentation scenario.
Augmentation potential	claude-sonnet-5	4/5	AI tools significantly speed up detection of data discrepancies, outliers, and protocol deviations, letting human auditors focus on judgment-intensive review rather than manual data scanning.
Task automatability	claude-haiku-4-5-20251001	2/5	Quality control audits require nuanced judgment about data integrity, contextual understanding of clinical workflows, and decision-making on what constitutes proper usage. While AI can assist with pattern detection and flagging anomalies, end-to-end autonomous auditing with 50% time savings at equal quality is not yet demonstrable; human review remains essential for validation.
Task automatability	claude-sonnet-5	3/5	AI can flag anomalies, missing fields, and inconsistencies in structured clinical data efficiently, but comprehensive audits requiring regulatory judgment, protocol interpretation, and sign-off still need human oversight, so only partial time savings are achievable end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical audits are often subject to regulatory requirements (FDA, GCP, HIPAA) and may require documented sign-off by qualified personnel. Liability exposure for missed errors in clinical data is asymmetric and high, creating strong organizational and legal friction against full automation without human accountability.
Adoption barriers	claude-sonnet-5	4/5	Clinical trial data audits fall under GxP/FDA regulatory frameworks requiring documented human review and accountability, creating strong compliance-driven barriers to full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI-based data quality tools require significant setup, integration, and ongoing oversight to prevent false positives in safety-critical clinical contexts. Combined with mandatory human validation, the all-in cost is comparable to or exceeds direct human labor for thorough audits.
Cost vs. human wage	claude-sonnet-5	3/5	Automated validation rules reduce manual review time substantially, but the need for qualified human auditors to interpret results and ensure regulatory compliance keeps overall costs only moderately below fully manual audits.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	Data validation tools exist and some AI-assisted anomaly detection is deployed, but comprehensive audit automation that reliably judges 'proper usage' and completeness across varied clinical systems remains immature. Most deployed products handle narrow, well-defined checks rather than the full scope of a quality control audit.
Technical feasibility today	claude-sonnet-5	3/5	Clinical data management platforms (e.g., Medidata, Oracle Clinical) include automated edit checks and validation rules deployed in production, but full audit workflows with root-cause analysis and compliance judgment remain largely manual or hybrid.

Design forms for receiving, processing, or tracking data.

CI 25–43 · exposure 33 · augmentation 63 · importance 4.0/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Clinical data management remains traditional and highly regulated; adoption of AI for form design is nascent with most organizations still relying on manual design processes. Pilot projects exist, but production-scale AI form automation in healthcare is limited by compliance and institutional friction.
Sector adoption velocity	claude-sonnet-5	2/5	Clinical research and pharma sectors are historically slower adopters of AI tools due to regulatory conservatism, though EDC vendors are beginning to integrate AI features incrementally.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist form designers by generating templates, suggesting field types, and automating layout, moderately raising productivity. However, the assistance is confined to drafting and ideation; compliance, user testing, and final validation remain human responsibilities.
Augmentation potential	claude-sonnet-5	4/5	AI can significantly speed up initial form drafting, suggest standard fields/edit checks based on CDISC standards, and reduce manual design time while a human validates and finalizes the output.
Task automatability	claude-haiku-4-5-20251001	2/5	Form design requires domain expertise, user research, and iterative refinement that AI struggles with end-to-end. While AI can draft form templates or suggest field structures, creating clinically compliant, user-tested forms that meet regulatory requirements demands human judgment and validation that prevents the 50% time-saving threshold.
Task automatability	claude-sonnet-5	3/5	AI can draft form structures, field lists, and edit checks from templates or protocols, but final forms require validation against protocol requirements, regulatory standards, and system integration that need human review.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical data systems fall under FDA/HIPAA regulation, and form design directly impacts data integrity and patient safety. Regulatory bodies and institutional oversight committees often require human accountability and sign-off on data collection instruments, creating legal liability barriers to full automation.
Adoption barriers	claude-sonnet-5	3/5	No strict licensure requirement for form design itself, but regulatory standards (CDISC, FDA) and audit trails create moderate compliance friction requiring qualified human sign-off.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI-assisted form design tools are relatively inexpensive, but end-to-end automation remains incomplete. The human cost of validation, compliance review, and user testing typically exceeds AI tool costs, keeping the ratio unfavorable for full substitution.
Cost vs. human wage	claude-sonnet-5	3/5	AI can speed up drafting and reduce iteration time, but human clinical data managers still must validate and finalize forms for regulatory compliance, keeping costs roughly comparable when factoring in oversight.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	AI tools can assist with form drafting (e.g., template generation, field suggestions), but no deployed product reliably performs independent clinical form design end-to-end. Existing solutions require substantial human oversight and domain expertise to ensure HIPAA/FDA compliance and clinical accuracy.
Technical feasibility today	claude-sonnet-5	2/5	Some EDC platforms (e.g., Medidata, Veeva) offer AI-assisted form-building templates and suggestions, but robust end-to-end automated design of compliant clinical data forms is not yet standard production practice.

Monitor work productivity or quality to ensure compliance with standard operating procedures.

CI 25–39 · exposure 38 · augmentation 75 · importance 4.0/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Healthcare data management remains heavily regulated and risk-averse; while some larger institutions pilot automated monitoring, widespread production deployment is slow due to liability concerns and the need for human validation of any automated compliance determinations.
Sector adoption velocity	claude-sonnet-5	2/5	Pharma and clinical research sectors are cautious adopters of AI due to regulatory scrutiny and validation requirements, so adoption of automated compliance monitoring remains slow and pilot-stage.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI excels at continuous automated monitoring, flagging anomalies, and generating exception reports that a clinical data manager can then investigate and act upon, substantially reducing the manual workload of reviewing logs and spotting quality drift.
Augmentation potential	claude-sonnet-5	4/5	AI-driven analytics and automated flagging tools can meaningfully assist data managers by surfacing outliers or deviations for human review, improving efficiency while humans retain final judgment.
Task automatability	claude-haiku-4-5-20251001	3/5	AI can monitor and flag deviations from standard operating procedures via log analysis, data quality checks, and pattern detection, but current systems lack the contextual judgment to fully assess compliance intent or handle exceptions that require clinical judgment without human review.
Task automatability	claude-sonnet-5	2/5	AI can flag anomalies or deviations in data logs, but judging compliance with SOPs requires contextual understanding of protocols and consequences that current systems can only partially handle, not fully end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical data management operates under HIPAA, FDA, and GCP regulations where compliance audit trails must often be signed off by a qualified clinical data manager; organizational policies typically require human accountability for quality assurance decisions.
Adoption barriers	claude-sonnet-5	4/5	Clinical trial data management is heavily regulated (GxP, FDA 21 CFR Part 11), requiring documented human oversight and accountability for compliance monitoring, creating strong barriers to full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Initial AI system setup, integration with existing clinical data infrastructure, and required human oversight to validate findings make the all-in cost comparable to or higher than a full-time monitor, especially for smaller operations.
Cost vs. human wage	claude-sonnet-5	2/5	Building and validating AI monitoring systems for regulated clinical data requires significant validation, oversight, and compliance documentation, keeping costs closer to human-level rather than dramatically cheaper.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Products exist for audit logging and quality monitoring in healthcare IT, but they require substantial manual configuration, human interpretation of alerts, and integration with institutional workflows; production reliability remains variable across diverse clinical data environments.
Technical feasibility today	claude-sonnet-5	2/5	Some clinical data management platforms include automated query checks and audit trail monitoring, but comprehensive SOP compliance oversight still relies heavily on human review in production settings.

Design and validate clinical databases, including designing or testing logic checks.

CI 25–37 · exposure 33 · augmentation 63 · importance 4.5/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Healthcare and clinical research remain among the slowest sectors for AI automation due to regulatory requirements, risk aversion, and the critical nature of data integrity. Adoption is primarily in pilot and early research phases rather than production displacement of clinical data managers.
Sector adoption velocity	claude-sonnet-5	2/5	Pharma and clinical research organizations are historically slow adopters of AI for core validated systems due to regulatory caution, though software vendors are beginning to pilot AI-assisted tools.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can meaningfully assist clinical data managers by suggesting schema designs, auto-generating test cases, and flagging potential data quality issues, thereby accelerating validation workflows. However, the human expert must remain in control of final design decisions and regulatory sign-off.
Augmentation potential	claude-sonnet-5	4/5	AI can meaningfully speed up drafting of database structures, edit check specifications, and test case generation, giving clinical data managers a significant productivity boost while they retain final validation responsibility.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can assist with generating database schemas and test cases, designing and validating clinical databases requires deep domain knowledge, regulatory understanding, and critical judgment about data integrity that current systems cannot reliably perform end-to-end. Significant human oversight and iteration remain necessary.
Task automatability	claude-sonnet-5	3/5	AI can generate database schemas, edit checks, and logic validation scripts from CRF specifications, but human review is needed to ensure regulatory compliance and catch domain-specific edge cases, so only partial time savings are realized end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Strong barriers exist: FDA and regulatory guidance require documented, validated databases with human accountability; clinical data validation carries high liability for errors; and organizational risk tolerance is low given patient safety implications. Regulatory frameworks effectively mandate human sign-off on database design.
Adoption barriers	claude-sonnet-5	4/5	Clinical trial databases fall under GxP/21 CFR Part 11 and similar regulations requiring validated systems and documented human sign-off, creating substantial compliance and liability barriers to full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Current AI tools for database design and validation still require substantial human review, rework, and oversight, making the all-in cost comparable to or higher than direct human performance. The integration overhead and error correction burden limit cost savings.
Cost vs. human wage	claude-sonnet-5	3/5	AI can cut time on drafting logic checks and schema templates, but the need for validation, regulatory documentation, and expert oversight keeps overall costs closer to comparable rather than order-of-magnitude cheaper.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	No deployed products today reliably design and validate clinical databases independently. Tools exist for code generation and testing assistance, but clinical data validation involves regulatory compliance (21 CFR Part 11, ICH guidelines) and complex business logic that require human expertise and cannot be delegated to production AI systems.
Technical feasibility today	claude-sonnet-5	2/5	Some clinical data management platforms incorporate AI-assisted edit check generation and validation scripting, but these are narrow-scope add-ons rather than fully autonomous database design systems used broadly in production.

Train staff on technical procedures or software program usage.

CI 25–36 · exposure 25 · augmentation 63 · importance 3.1/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Healthcare IT and clinical settings are relatively conservative adopters of automation; training remains a function organizations prefer to keep under direct human management for compliance and quality assurance. Adoption of AI-assisted (not autonomous) training tools is slow in clinical environments.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and clinical research organizations are adopting AI tools for documentation and training support at a moderate pace, but formal validated training programs adopt new tools cautiously due to compliance concerns.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist trainers by generating course outlines, creating video clips, answering routine questions via chatbot, or flagging common learner errors—moderately improving productivity. However, the core task of live instruction and interactive problem-solving remains trainer-led.
Augmentation potential	claude-sonnet-5	4/5	AI can substantially help trainers by drafting training materials, quizzes, and job aids, and by answering routine software questions, improving efficiency while humans retain oversight of certification and compliance.
Task automatability	claude-haiku-4-5-20251001	2/5	Training delivery requires dynamic explanation, real-time question handling, and personalized feedback—tasks where current AI falls short of 50% time savings at equal quality. While AI can generate training materials or draft procedures, synchronous staff instruction and adaptive troubleshooting remain human-centric.
Task automatability	claude-sonnet-5	2/5	AI can generate training materials and answer procedural questions, but delivering hands-on training, adapting to trainee needs, and hands-on software walkthroughs still require significant human involvement.-full end-to-end training delivery is not yet replaceable at equal quality.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Training clinical staff on data management software often occurs in regulated environments (healthcare, HIPAA) and involves certification or competency sign-off requirements. Organizations typically require human trainers to verify understanding and assume liability for staff readiness, creating legal and compliance friction.
Adoption barriers	claude-sonnet-5	3/5	Clinical data management often has SOP and regulatory compliance requirements (e.g., GCP training records) that may require documented human-led or human-verified training, creating moderate friction against full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI-generated training content and chatbot support have moderate costs, but integrating them with oversight, updating for new software versions, and maintaining quality oversight approaches human trainer wages rather than undercutting them significantly.
Cost vs. human wage	claude-sonnet-5	3/5	AI can cheaply produce training content and answer FAQs, but the overall training process (scheduling, hands-on practice, certification) still requires human time, making the cost advantage moderate rather than transformative.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	Some products (e.g., automated onboarding platforms, chatbot FAQs) exist but are narrow in scope and often fail on complex questions or hands-on software troubleshooting. No deployed system reliably handles the full breadth of live training delivery with high learner satisfaction and competency verification.
Technical feasibility today	claude-sonnet-5	2/5	AI-generated tutorials, chatbots, and documentation exist, but production systems rarely handle full staff training on clinical data systems reliably without human trainers overseeing comprehension and compliance.

Contribute to the compilation, organization, and production of protocols, clinical study reports, regulatory submissions, or other controlled documentation.

CI 25–34 · exposure 33 · augmentation 75 · importance 3.4/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Clinical research and pharma operations lag in adopting autonomous AI systems due to regulatory constraints and risk aversion. While pilots of AI-assisted documentation exist, production displacement remains minimal; most adoption is limited to supplementary tools rather than agents handling controlled submissions.
Sector adoption velocity	claude-sonnet-5	2/5	Pharma and clinical research sectors are historically slow adopters of AI for regulated documentation due to compliance concerns, though pilots are emerging in medical writing assistance.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI can meaningfully assist by auto-generating document sections, organizing data, flagging inconsistencies, and providing regulatory compliance suggestions, allowing clinical data managers to review and validate rather than build from scratch. Current tools demonstrably raise productivity when human oversight remains central.
Augmentation potential	claude-sonnet-5	4/5	AI can meaningfully speed up drafting, formatting, and summarizing sections of protocols and reports, significantly aiding clinical data managers while they retain responsibility for accuracy and compliance.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can assist with document compilation, organization, and formatting, the task requires significant human judgment on regulatory compliance, protocol accuracy, and data integrity that current systems cannot reliably handle end-to-end. The controlled documentation domain demands verification and sign-off that prevents the ≥50% time-saving threshold from being met without substantial human oversight.
Task automatability	claude-sonnet-5	3/5	AI can draft sections, summarize data, and assemble boilerplate content in clinical study reports and protocols, but final compilation requires integrating complex trial data, ensuring regulatory compliance, and expert review, limiting full automation.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Regulatory frameworks (FDA 21 CFR Part 11, ICH-GCP) require documented human accountability and sign-off on clinical documentation. Liability for submission errors, data integrity obligations, and the requirement that qualified professionals certify submissions create strong legal and organizational barriers to full automation.
Adoption barriers	claude-sonnet-5	4/5	Regulatory submissions require sign-off by qualified professionals and adherence to strict GxP/regulatory standards (e.g., FDA, EMA), creating strong liability and compliance barriers to full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Integration costs for AI systems in regulated clinical environments are high due to validation, audit requirements, and compliance infrastructure. The loaded wage for experienced clinical data managers remains competitive with the all-in cost of AI solutions including oversight and quality assurance labor.
Cost vs. human wage	claude-sonnet-5	2/5	AI drafting tools reduce some labor but the extensive validation, quality control, and regulatory review still required keep costs closer to human-comparable rather than order-of-magnitude cheaper.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	No deployed product reliably handles full clinical documentation compilation and regulatory submission generation independently. Existing tools support templates and organization but lack the domain-specific validation, regulatory knowledge integration, and audit-trail requirements that production systems in pharma/biotech demand.
Technical feasibility today	claude-sonnet-5	2/5	Some vendors offer AI-assisted drafting tools for regulatory documents, but production-grade, reliable systems fully handling clinical study report compilation without heavy human oversight are not yet widespread.

Develop project-specific data management plans that address areas such as coding, reporting, or transfer of data, database locks, and work flow processes.

CI 25–32 · exposure 25 · augmentation 63 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Clinical research and CROs are digitizing but conservatively; adoption of AI for core data governance tasks remains pilot-stage because of regulatory caution and the need for human experts to validate outputs. Organizational friction and compliance risk slow deployment.
Sector adoption velocity	claude-sonnet-5	3/5	Clinical/pharma sectors are moderately digitized with growing AI pilot use in data management, but production-grade autonomous plan generation remains uncommon.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist by drafting templates, suggesting coding standards, and flagging workflow risks, improving a data manager's efficiency on routine sections. However, augmentation is limited to lower-level drafting; final synthesis and regulatory judgment remain human-driven.
Augmentation potential	claude-sonnet-5	4/5	AI can meaningfully speed up drafting of standard plan sections, coding conventions, and workflow documentation, giving data managers a strong productivity boost while they retain final judgment.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can draft sections of data management plans (coding standards, workflow templates), these plans require domain expertise, regulatory alignment, and project-specific customization that current systems handle poorly. The task involves strategic judgment and stakeholder input that AI cannot fully replace—at best, AI assists with boilerplate generation, not end-to-end planning.
Task automatability	claude-sonnet-5	2/5	Drafting a data management plan requires synthesizing regulatory requirements, study protocol specifics, and cross-functional workflow decisions that current AI can assist with but not reliably originate end-to-end without heavy expert review.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical data management is subject to FDA, ICH, and protocol regulations; data management plans must be signed off by qualified individuals and integrated with clinical governance frameworks. Liability for data integrity and regulatory compliance creates strong human-accountability requirements that prevent full automation.
Adoption barriers	claude-sonnet-5	3/5	While not formally licensed work, DMPs are subject to GxP/regulatory scrutiny and sponsor audit requirements, creating liability and compliance friction that slows full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	An experienced clinical data manager's labor is specialized and high-value; AI tools for partial assistance (draft generation, template filling) reduce time modestly but do not approach order-of-magnitude savings, especially when oversight and rework are factored in.
Cost vs. human wage	claude-sonnet-5	2/5	Given the need for extensive expert validation against protocol and regulatory requirements, AI-assisted drafting saves some time but the oversight burden keeps costs closer to comparable rather than an order of magnitude cheaper.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	No deployed product reliably generates compliant, project-specific data management plans independently. Tools exist for documentation and workflow design, but they require heavy human oversight and iteration to meet regulatory and clinical standards; none work at scale without expert review.
Technical feasibility today	claude-sonnet-5	2/5	No deployed clinical data management product autonomously generates compliant, protocol-specific DMPs at production scale; AI is used mainly for drafting sections or templates under human oversight.

Evaluate processes and technologies, and suggest revisions to increase productivity and efficiency.

CI 25–30 · exposure 25 · augmentation 63 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Healthcare and clinical research sectors are slower to adopt AI-driven operational recommendations due to regulatory conservatism and the high cost of errors. While early pilots exist, most organizations still rely on traditional process improvement methodologies and human expertise rather than AI-suggested revisions.
Sector adoption velocity	claude-sonnet-5	2/5	Pharma and clinical research sectors are historically slower adopters of AI-driven process automation due to regulatory caution, validation requirements, and legacy systems, despite growing interest in digital transformation.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist clinical data managers by analyzing workflow logs, identifying performance metrics, and generating preliminary optimization suggestions that humans then evaluate and refine. This assistive role is practical and increasingly deployed, though it remains supplementary to expert judgment rather than transformative of the overall task.
Augmentation potential	claude-sonnet-5	4/5	AI can meaningfully assist by analyzing large datasets on process performance, identifying bottlenecks, benchmarking against best practices, and drafting improvement proposals for human review and validation.
Task automatability	claude-haiku-4-5-20251001	2/5	Evaluation of processes and suggesting revisions requires domain expertise, contextual judgment, and stakeholder understanding that current AI systems struggle with end-to-end. While AI can analyze data and identify bottlenecks, synthesizing recommendations that account for clinical compliance, organizational constraints, and implementation feasibility remains heavily dependent on human judgment.
Task automatability	claude-sonnet-5	2/5	This requires domain-specific judgment about clinical data workflows, regulatory context, and organizational realities that AI cannot fully replicate end-to-end without heavy human oversight, though it can assist with analysis and drafting recommendations.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical data management operates under strict regulatory frameworks (FDA, HIPAA, ICH) where process changes must be documented, validated, and often approved by compliance and quality assurance functions. The liability and regulatory risk associated with automated process recommendations create substantial organizational friction and legal barriers to full automation.
Adoption barriers	claude-sonnet-5	3/5	Clinical data management operates under regulatory frameworks (GCP, FDA requirements) that necessitate human accountability for process changes, though the evaluation task itself isn't formally licensed work.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Current AI tools for process analysis and recommendation require significant setup, domain customization, and human expert review to validate outputs. When accounting for integration, prompt engineering, and necessary human oversight, the all-in cost remains comparable to or exceeds direct hiring of process improvement specialists.
Cost vs. human wage	claude-sonnet-5	2/5	While AI-assisted analysis is cheap per query, the human expertise needed to validate findings, understand regulatory constraints, and implement change management keeps overall cost comparable to or only modestly cheaper than human-led evaluation.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	No mature product demonstrably performs comprehensive process evaluation and revision recommendation in clinical data management environments at scale. Some workflow analytics and optimization tools exist, but they typically require substantial configuration, human interpretation of results, and validation before actionable recommendations emerge.
Technical feasibility today	claude-sonnet-5	2/5	AI tools can analyze process metrics and suggest generic efficiency improvements, but no deployed product reliably evaluates clinical data management processes and generates validated, context-aware technology recommendations in production.

Develop technical specifications for data management programming and communicate needs to information technology staff.

CI 25–30 · exposure 25 · augmentation 63 · importance 3.6/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Clinical and healthcare IT sectors show cautious, slower adoption of AI for critical data governance tasks due to regulatory constraints, risk aversion, and the requirement for human accountability in compliance-sensitive domains. Adoption remains largely in pilot phases rather than production deployment.
Sector adoption velocity	claude-sonnet-5	2/5	Pharma and clinical research sectors are historically slower adopters of AI-driven documentation tools due to regulatory caution, though some pilot programs exist for using AI in specification drafting.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can meaningfully assist clinical data managers by drafting specification sections, suggesting technical approaches, or auto-generating documentation templates, improving productivity in the writing and structuring phases while the human retains responsibility for accuracy, compliance, and IT feasibility assessment.
Augmentation potential	claude-sonnet-5	4/5	AI can meaningfully assist by drafting boilerplate specifications, summarizing requirements, and generating documentation templates, improving efficiency while the human retains oversight and final judgment.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can assist in drafting technical specifications and documentation, the task requires deep understanding of clinical workflows, regulatory requirements, and organizational IT infrastructure that currently demands human expertise. End-to-end automation with 50% time savings at equal quality is not reliably achievable without substantial human oversight and iterative refinement.
Task automatability	claude-sonnet-5	2/5	This task requires deep understanding of clinical trial protocols, regulatory requirements (e.g., CDISC, FDA), and stakeholder negotiation, which current AI can partially assist with drafting but cannot fully own end-to-end.dedd LLMs can help draft specs but domain judgment and cross-functional communication remain human-centric.It's not a full 50% time-saving automation case without heavy human oversight.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical data management operates under strict regulatory frameworks (HIPAA, 21 CFR Part 11, clinical trial regulations), and data governance decisions carry significant liability and compliance risk. IT implementation decisions require accountability and sign-off from qualified personnel, creating substantial organizational and legal barriers to full automation.
Adoption barriers	claude-sonnet-5	3/5	While not strictly licensed work, clinical data management specifications are subject to regulatory scrutiny (GCP, FDA audit trails) and require sign-off by qualified personnel, creating moderate organizational and compliance friction.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Using AI assistance to draft specifications still requires significant human review, validation, and rework by domain experts, making the all-in cost of AI-assisted specification development comparable to or higher than having a clinical data manager develop it directly without AI assistance.
Cost vs. human wage	claude-sonnet-5	2/5	Given the need for domain expertise, regulatory compliance, and iterative stakeholder communication, AI assistance reduces some drafting time but does not yet significantly undercut the loaded cost of a skilled clinical data manager.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	No deployed product reliably performs full technical specification development for clinical data systems end-to-end. Some LLMs can generate specification templates or assist with documentation drafting, but they lack the domain-specific clinical and IT knowledge needed for production-grade specifications that IT teams can implement directly.
Technical feasibility today	claude-sonnet-5	2/5	No mature deployed product autonomously generates and negotiates clinical data management technical specifications in production; existing AI tools are used piecemeal for documentation drafting only.

Confer with end users to define or implement clinical system requirements such as data release formats, delivery schedules, and testing protocols.

CI 16–32 · exposure 20 · augmentation 63 · importance 3.8/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Healthcare remains a regulated, conservative sector with low overall AI adoption in core clinical operations; clinical data management is highly specialized and still largely manual, with limited public evidence of deep AI agent deployment in requirement-definition workflows.
Sector adoption velocity	claude-sonnet-5	3/5	Healthcare/clinical trials sectors are adopting AI for documentation and data tasks but requirements-gathering conversations remain largely human-led, so adoption is moderate and uneven.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist by drafting requirement summaries, analyzing existing protocols, or flagging inconsistencies in data formats, helping a human manager organize and prepare for conferences. However, the creative and relational work of conferring remains human-led.
Augmentation potential	claude-sonnet-5	4/5	AI can strongly assist by drafting requirement documents, summarizing meeting notes, generating test protocol templates, and flagging inconsistencies, boosting the manager's productivity while they remain in the loop.
Task automatability	claude-haiku-4-5-20251001	2/5	Conferring with end users requires understanding nuanced clinical needs, negotiating trade-offs, and building consensus—tasks demanding human judgment and relationship management. AI can assist in drafting documents or summarizing requirements, but cannot reliably conduct the full stakeholder dialogue and implement agreements end-to-end with equal quality.
Task automatability	claude-sonnet-5	2/5	This requires live stakeholder negotiation, contextual judgment about competing requirements, and iterative clarification that current AI cannot reliably conduct end-to-end without heavy human involvement.'
Adoption barriers	claude-haiku-4-5-20251001	4/5	Clinical system requirements carry regulatory and liability weight under HIPAA and FDA oversight; organizations typically require a qualified human (often credentialed) to formally define and sign off on data protocols and delivery formats to maintain accountability and compliance.
Adoption barriers	claude-sonnet-5	3/5	No strict licensing requirement, but clinical data governance, regulatory compliance (e.g., FDA, GxP), and organizational trust in interpreting stakeholder needs create moderate friction against full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	1/5	The labor cost of a clinical data manager with domain expertise and stakeholder relationships is substantial; AI inference and oversight of such sensitive clinical conversations would still require human validation and course-correction, making the all-in cost competitive with or higher than direct human performance.
Cost vs. human wage	claude-sonnet-5	2/5	Human elicitation still requires domain expertise and relationship management; AI can support documentation but the core conferring activity still requires paid human time, limiting cost savings.
Technical feasibility today	claude-haiku-4-5-20251001	1/5	No deployed product reliably performs real-time requirement definition conferences with clinical end users in production settings. Existing clinical data management software supports workflow and documentation, but does not autonomously negotiate or define system requirements through interactive sessions.
Technical feasibility today	claude-sonnet-5	2/5	AI meeting assistants and requirements-drafting tools exist but no deployed product autonomously confers with end users to define clinical system requirements at production reliability.

Related occupations — Computer & Mathematical

How to read this

A high substitution score does not mean this job disappears — it means a large share of its current tasks face replacement pressure, so the mix of tasks is likely to change. High augmentation alongside substitution typically means the occupation reorganizes around the protected tasks. Wide confidence intervals mean the rater panel disagreed: treat those scores as open questions, not verdicts.

What would change this score

New model capabilities (automatability, feasibility), falling inference costs (cost ratio), regulation and licensing shifts (barriers), and measured sector adoption (velocity) all re-enter at every index release. Each release is recomputed, versioned and kept queryable — scores are claims with a date on them, not permanent labels.